Tag Archives: rna

BioMarin Buys Prosensa Backs Up Troubled Drug

Biotech BioMarin Pharmaceutical (BMRN) agreed Monday to pay $680 million in cash for Prosensa Holding, developer of a muscular-dystrophy drug with a checkered history. Prosensa soared 63%, while BioMarin slipped a fraction in early trading in the stock market today. The deal also included two milestone payments of $80 million each if Prosensa’s (RNA) lead drug drisapersen is approved for Duchenne’s muscular dystrophy (DMD) in the U.S. no later

Prosensa Muscular Dystrophy Data Send Stock Rising

Beleaguered biotech stock Prosensa (RNA) was up 8% in midday trading on the stock market today after the company reported new data on its Duchenne muscular dystrophy candidate late Monday. Earlier, Prosensa stock was up as much as 30%, to 8.80, a six-month high. Prosensa followed up on DMD patients six months after they’d gone through a 24-week round of treatment with its drug drisapersen. Prosensa reported in September that after the initial